Dobu AHFS

AHFS DI Essentials
Page 1 of 15
Dobutamine (Systemic)
Introductory Information
Dobutamine is a synthetic sympathomimetic that is structurally related to dopamine and generally is
considered a relatively selective 1-adrenergic agonist.
Class: 12:12.08.08 Selective beta-1-Adrenergic Agonists; au100 (VA primary);
Brands*: Dobutrex
*also
available generically
Generic Name: Dobutamine Hydrochloride

CAS Number: 49745-95-1
Uses
Cardiac Decompensation, Shock, and CHF
Used to increase cardiac output in the short-term treatment of cardiac decompensation caused by
depressed contractility from organic heart disease, cardiac surgical procedures, cardiac arrest
(ACLS; see CPR under Uses), or acute MI (see MI under Uses).103, 107, 110, 111, a, b
May be particularly useful in the management of cardiogenic shock, including drug-induced
cardiogenic shock, in patients with normal DBP and SBP >100 mm Hg, since the drug provides the
best sympathomimetic support.104, 112
May be preferable to dopamine in the period immediately following cardiopulmonary bypass
surgery.b
Safety and efficacy in the long-term (e.g., exceeding 48 hours) treatment of CHF have not been
established.103, 107, 109, a, b Patients with NYHA class IV disease appear at particular risk of adverse
effects of long-term cAMP-dependent inotropic therapy.a
May be ineffective and potentially harmful in marked mechanical obstruction (e.g., severe valvular
aortic stenosis).b
Should not be used alone in severely hypotensive patients (e.g., when SBP is <100 mm Hg).b
Should not be used in patients with drug-induced distributive shock, since the drug may worsen
hypotension by further decreasing systemic vascular resistance.112
CPR
Used as a potent inotropic agent to increase cardiac output in ACLS during CPR.110, b
May be particularly useful for low cardiac output secondary to poor myocardial function, such as
following cardiac arrest.110
Predominant -adrenergic effects increase myocardial contractility in a dose-dependent manner and
decrease left ventricular filling pressures.110
mk:@MSITStore:F:\Kuliah%20Apoteker%2081\ebook\AHFS%202011.chm::/nymayn... 7/30/2015
AHFS DI Essentials
Page 2 of 15
Arterial blood pressure may remain unchanged due to reflex peripheral vasodilation (baroreceptor
mediated) in response to increased stroke volume.110
Useful in the management of postresuscitation shock (e.g., when combined with dobutamine).110, c
MI
Although the manufacturers state that safety following MI has not been established, use in
combination with dopamine in acute MI management is recommended by the ACC and AHA for
the management of heart failure and low-output syndromes associated with left ventricular
dysfunction and for inotropic support following hypotension management associated with right
ventricular ischemia.111
May be useful as an adjunct (to increase cardiac output) to volume replacement in patients with right
ventricular infarction, since dopamine may increase pulmonary vascular resistance.b
Dosage and Administration
Administration
Usually administered by IV infusionb
Has also been administered by intraosseous infusion .110
IV Infusion
Infuse IV using an infusion pump or other apparatus to control the rate of flow and avoid inadvertent
administration of a bolus of drug.107, a, b
Commercially available premixed dobutamine hydrochloride in 5% dextrose should be administered
only by IV infusion via a suitable catheter or needle.107
Do not be use in series connections.107
When the commercially available IV infusion solution of dobutamine hydrochloride in 5% dextrose
is used, the accompanying labeling should be consulted for proper methods of administration and
other associated precautions.b
Dilution
The concentrate for injection must be diluted prior to administration; alternatively, commercially
available diluted injections for IV infusion may be used.103, b
20 mL of the concentrate for injection should be diluted in at least 50 mL of diluent and 40 mL of
concentrate should be diluted in at least 100 mL of diluent.b
The concentration used is individualized according to patient dosage and fluid requirements, but
should not exceed 5000 mcg (5 mg)/mL.103, 110, a, b
>Dilution of Concentrate for Injection for IV Infusion103, b
Amount of
Add (volume of
To Compatible IV Solution
Concentrate
concentrate)
(volume of solution)
To Make (final dilution

concentration)
AHFS DI Essentials
250 mg
250 mg
250 mg
250 mg
20 mL
20 mL
20 mL
20 mL
Page 3 of 15
1L
500 mL
250 mL
50 mL
250 mcg (0.25 mg)/mL

500 mcg (0.5 mg)/mL
1000 mcg (1 mg)/mL
5000 mcg (5 mg)/mL
Rate of Administration
Avoid bolus administration.b
Rate of IV infusion varies according to individual dose requirements titrated to response.103, 107, 110,
a, b
Initiate at a slow rate (e.g., 0.5-1 mcg/kg per minute) and carefully adjust at intervals of a few
minutes according to response;b usually 2-20 mcg/kg per minute is needed.103, 107, 110, a, b
Intraosseous Administration
When IV administration is not possible, dobutamine may be given by intraosseous infusion for
emergency uses such as CPR.110, 112
Limit intraosseous administration to personnel well trained in the technique.100
Place a cannula in a noncollapsible marrow venous plexus; such access often can be achieved in 3060 seconds.100 Use a rigid needle, preferably a specially designed intraosseous or Jamshidi-type
bone marrow needle; a styleted needle is preferred to prevent obstruction of the needle with cortical
bone.100
Insert the intraosseous needle into the anterior tibial bone marrow; alternatively, the distal femur,
medial malleolus, or anterior superior iliac spine can be used.100 In older children and adults,
intraosseous cannulas also have been inserted successfully into the distal radius or ulna in addition to
the proximal tibia.100
Successful placement outside the hospital (e.g., by emergency medical services) generally is more
difficult in older than in younger children.100
Onset of action and systemic concentrations are comparable to those achieved with intravascular
administration.100, 112
Dilution
Same as those for IV infusion. (See Dilution under IV Infusion.)
Rate of Administration
Intraosseous infusion rates are the same as those for IV infusion.100 (See Rate of Administration
under IV Infusion.)
Administration Risks
Complications are uncommon (less than 1% of patients), and include tibial fracture, lower-extremity
compartment syndrome, extravasation, and osteomyelitis; careful technique can minimize the
risk.100 Local effects on bone marrow and bone growth appear to be minimal.100 Risk of
microscopic pulmonary fat and bone marrow emboli does not appear to be increased.100
Dosage
AHFS DI Essentials
Page 4 of 15
Available as dobutamine hydrochloride; dosage expressed in terms of dobutamine.103, 107, a, b

Hemodynamic end points rather than a specific dose should be used to optimize therapy.110, 112
Individual response to dobutamine is variable, and infusion rate should be titrated to achieve the
desired clinical response.b
Rate and duration should be carefully adjusted according to patient response as indicated by heart
rate, BP, urine flow, peripheral perfusion, presence of ectopic heartbeats, and, whenever possible, by
measurement of central venous or pulmonary wedge pressure and cardiac output.103, 107, a, b
Pediatric Patients
Pharmacokinetics and clinical responses to specific doses vary widely.110
Usually initiate slowly (e.g., 0.5-1 mcg/kg per minute).b
Cardiac Decompensation and Shock
>IV or Intraosseous
Usually, 2-20 mcg/kg per minute is needed to increase cardiac output.110, b
CPR
>IV or Intraosseous
Usually, 2-20 mcg/kg per minute is needed to increase cardiac output.110, 112, b
MI
>IV or Intraosseous
Adults
Individual response to dobutamine is variable, and infusion rate should be titrated to achieve the
desired clinical response.103, 107, 110, a, b
Initiate at a slow rate (e.g., 0.5-1 mcg/kg per minute) and carefully adjust at intervals of a few
minutes according to response.b
Dobutamine has been infused for up to 72 hours without decreased effectiveness.b
Cardiac Decompensation and Shock
>IV or Intraosseous
CPR
>IV or Intraosseous
MI
>IV or Intraosseous
Prescribing Limits
AHFS DI Essentials
Page 5 of 15
Pediatric Patients
IV or Intraosseous
Dosages >20 mcg/kg per minute may produce tachycardia and ventricular ectopy and could induce
or exacerbate myocardial ischemia.104, 112
Adults
IV or Intraosseous
Dosages >20 mcg/kg per minute often increase heart rate by more than 10%, and such increases
potentially could induce or exacerbate myocardial ischemia.104, 112
Rarely, dosages as great as 40 mcg/kg per minute,103, 107, 112 but these may substantially increase
adverse effects, (e.g., tachycardia, hypotension) and usually should be avoided.104, 112
Special Populations
Hepatic Impairment
No specific hepatic dosage recommendations.a
Renal Impairment
No specific renal dosage recommendations.a
Geriatric Patients
Initiate therapy at lower end of usual range because of age-related decreases in hepatic, renal, and/or
cardiac function and concomitant disease and drug therapy.108 However, geriatric patients may
exhibit a substantially decreased response.110, 112
Cautions
Contraindications
Idiopathic hypertropic subaortic stenosis.
Known hypersensitivity to dobutamine hydrochloride or any ingredient in the formulation.103, 106,
107, a, b
Solutions containing dextrose may be contraindicated in patients with known allergy to corn or
corn products.107, a
Warnings/Precautions
Warnings
Cardiovascular Effects
Marked increases in heart rate and BP (especially systolic pressure) can occur.103, a, b Heart rate of
30 beats per minute or an increase in systolic BP of 50 mm Hg reported.b
Cardiovascular effects are usually dose related, and dosage should be reduced or the infusion
temporarily discontinued if such effects occur.b
Patients with preexisting hypertension are at increased risk of an exaggerated pressor response.103, a,
b
Patients with atrial fibrillation should be digitalized because of the risk of developing a rapid
ventricular response.103, a, b
AHFS DI Essentials
Page 6 of 15
Ectopic Activity
Can precipitate or exacerbate ventricular ectopic activity; rarely, causes ventricular tachycardia.103
Sensitivity Reactions
Hypersensitivity Reactions
Hypersensitivity, including skin rash, fever, eosinophilia, and bronchospasm, have been reported
occasionally.103, 107
Sulfites
Some formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis
and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.102, 103, 106,
107, a, b
Corn
Dextrose-containing solutions may be contraindicated in patients who are sensitive to corn or corn
products.107, a
General Precautions
Hypovolemia
Hypovolemia should be corrected with an appropriate plasma volume expander before initiating
dobutamine.103, 107, a, b
MI
Clinical experience insufficient to rule out possibility of intensified or extended myocardial
ischemia; use with extreme caution following MI.103, 107, a, b (See MI under Uses.)
Cardiac Mechanical Obstruction
No benefit may be apparent in the presence of marked mechanical obstruction (e.g., severe valvular
aortic stenosis).103, 107, a
Monitoring Parameters
Monitor ECG, BP and, when possible, cardiac output and pulmonary wedge pressure.103, 107, a, b
May produce slight reductions in serum potassium concentrations and hypokalemia may occur
rarely; monitor serum potassium concentrations.b
Specific Populations
Pregnancy
Category B.103, a
Lactation
Not known whether dobutamine is distributed into human milk.103 Caution if used in nursing
women.103
Pediatric Use
May increase cardiac output and systemic pressure in pediatric patients of all age groups.103, 107
Such increases generally are seen at lower infusion rates than those associated with substantial
tachycardia.103, 107
Premature neonates: May be less effective in increasing systemic BP without causing undue
tachycardia, and dobutamine has not been shown to provide any additional benefit when
AHFS DI Essentials
Page 7 of 15
administered to such infants who are already receiving optimal dopamine therapy.103, 107
Geriatric Use
Insufficient experience in patients 65 years of age to determine whether geriatric patients respond
differently than younger adults; some clinical experience showed no differences.a
Use with caution since renal, hepatic, and cardiovascular dysfunction and concomitant disease or
other drug therapy are more common in this age group.108, a However, geriatric patients generally
have a substantially reduced response to dobutamine.110, 112
Common Adverse Effects
Ectopic heartbeats, increased heart rate, elevations in BP, hypotension, phlebitis, local inflammatory
changes.103, a, b
Interactions
No evidence of interactions in clinical studies when used with atropine, cardiac glycosides (digoxin),
furosemide, heparin, lidocaine, morphine, nitrates, potassium chloride, or spironolactone.103, 103, a
Specific Drugs
Drug
Interaction
Cardiac effects of dobutamine are antagonized,
resulting in predominant -adrenergic effects and
-Adrenergic blocking agents increased peripheral resistance; dobutamine may
be ineffective103, a, b
Anesthetics, general (e.g.,
May increase cardiac irritability, resulting in
halogenated hydrocarbons
ventricular arrhythmias with usual dobutamine
[e.g., halothane],
dosesb
cyclopropane)
Potentiated effects on cardiac output and
Sodium nitroprusside
pulmonary wedge pressurea
Comments
Use
concomitantly
with cautionb
Use
concomitantly
with cautionb
Pharmacokinetics
Absorption
Onset
Onset occurs within 2 minutes after initiation of IV infusion; peaks within 10 minutes.b
Duration
Effects cease shortly after infusion discontinuance.b
Distribution
Extent
Not known if dobutamine crosses the placentab or is distributed into milk.103, b
Elimination
AHFS DI Essentials
Page 8 of 15
Metabolism
Metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) to an inactive
compound, 3-O-methyldobutamine, and by conjugation with glucuronic acid.b
Elimination Route
Conjugates of dobutamine and 3-O-methyldobutamine excreted mainly in urine and to a minor
extent in feces.b
Half-life
About 2 minutes.a, b
Stability
Storage
Parenteral
Pink discoloration indicates slight oxidation of the drug; however, there is no important loss of
potency if administered within the recommended time period.b
Store at 15-30C.b
Solutions of dobutamine hydrochloride in 5% dextrose should be protected from excessive heat or
freezing and stored at room temperature (25C); however, brief exposure of the solutions to
temperatures up to 40C does not adversely affect the products.107
Solutions diluted for IV infusion should be used within 24 hours; unused portions should be
discarded.b
Concentrate for Injection for IV Infusion
15-30C.103, b
Injection for IV Infusion
25C; may be exposed briefly to temperatures up to 40C.a Do not freeze.a
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Incompatible with strongly alkaline solutions.103, a, b
Should not be used in conjunction with other drugs or diluents containing both sodium bisulfite and
ethanol.103, b
Parenteral
Solution CompatibilityHID
Stable for 24 hours in dextrose 5 or 10%, dextrose 5% in sodium chloride 0.45 or 0.9%, dextrose 5%
in lactated Ringer's injection, Isolyte M with 5% dextrose, lactated Ringer's, Normosol -M with
5% dextrose, Osmitrol in water, sodium chloride 0.9%, and sodium lactate (1/6) M.103
Compatible
Dextrose 2.5% in half-strength Ringer's injection, lactated
AHFS DI Essentials
Page 9 of 15
Dextrose 5% in Ringer's injection, lactated

Dextrose 2.5% in sodium chloride 0.45%
Dextrose 5% in sodium chloride 0.45 or 0.9%
Dextrose 5% in water
Ringer's injection, lactated
Sodium chloride 0.45 or 0.9%
Incompatible
Sodium bicarbonate 5%
Drug Compatibility
Additives should not be introduced into the injection containers.a, 107
Since dobutamine dosage must be titrated according to response, other drugs generally should not be
added to the infusion fluid.c
>Admixture CompatibilityHID
Compatible
Amiodarone HCl
Atracurium besylate
Atropine sulfate
Ciprofloxacin
Dopamine HCl
Enalaprilat
Epinephrine HCl
Flumazenil
Hydralazine HCl
Isoproterenol HCl
Lidocaine HCl
Meperidine HCl
Meropenem
Metaraminol bitartrate
Morphine sulfate
Nitroglycerin
Norepinephrine bitartrate
Phentolamine mesylate
Phenylephrine HCl
Procainamide HCl
Propranolol HCl
Ranitidine HCl
Zidovudine
Incompatible
Acyclovir sodium
Alteplase
Aminophylline
Bumetanide
AHFS DI Essentials
Page 10 of 15
Calcium gluconate
Diazepam
Digoxin
Furosemide
Magnesium sulfate
Phenytoin sodium
Potassium phosphates
Sodium bicarbonate
Variable
Bretylium tosylate
Calcium chloride
Heparin sodium
Nitroglycerin with sodium nitroprusside
Potassium chloride
Verapamil HCl
>Y-Site CompatibilityHID
Compatible
Alcohol 10% in dextrose 5%
Amifostine
Amiodarone HCl
Argatroban
Atracurium besylate
Aztreonam
Bivalirudin
Bretylium tosylate
Calcium chloride
Calcium gluconate
Ciprofloxacin
Cladribine
Clarithromycin
Dexmedetomidine HCl
Diazepam
Diltiazem HCl
Docetaxel
Dopamine HCl
Dopamine HCl with lidocaine HCl
Dopamine HCl with nitroglycerin
Dopamine HCl with sodium nitroprusside
Doxorubicin HCl liposome injection
Enalaprilat
Epinephrine HCl
Etoposide phosphate
Famotidine
AHFS DI Essentials
Page 11 of 15
Fenoldopam mesylate
Fentanyl citrate
Fluconazole
Gemcitabine HCl
Granisetron HCl
Haloperidol lactate
Hetastarch in lactated electrolyte injection (Hextend)
Hydromorphone HCl
Inamrinone lactate
Insulin, regular (Humulin R)
Labetalol HCl
Levofloxacin
Lidocaine HCl
Lidocaine HCl with dopamine HCl
Lidocaine HCl with nitroglycerin
Lidocaine HCl with sodium nitroprusside
Linezolid
Lorazepam
Magnesium sulfate
Meperidine HCl
Milrinone lactate
Morphine sulfate
Nicardipine HCl
Nitroglycerin
Nitroglycerin with dopamine HCl
Nitroglycerin with lidocaine HCl
Nitroglycerin with sodium nitroprusside
Norepinephrine bitartrate
Oxaliplatin
Pancuronium bromide
Potassium chloride
Propofol
Ranitidine HCl
Remifentanil HCl
Sodium nitroprusside
Sodium nitroprusside with dopamine HCl
Sodium nitroprusside with lidocaine HCl
Sodium nitroprusside with nitroglycerin
Tacrolimus
Theophylline
Thiotepa
Tirofiban HCl
Vasopressin
Vecuronium bromide
Verapamil HCl
AHFS DI Essentials
Page 12 of 15
Zidovudine
Incompatible
Acyclovir sodium
Alteplase
Aminophylline
Amphotericin B cholesteryl sulfate complex
Cefepime HCl
Foscarnet sodium
Indomethacin sodium trihydrate
Lansoprazole
Pantoprazole sodium
Pemetrexed disodium
Phytonadione
Piperacillin sodium-tazobactam sodium
Thiopental sodium
Warfarin sodium
Variable
Cefepime HCI
Ceftazidime
Furosemide
Heparin sodium
Midazolam HCl
Actions
The main effect of therapeutic doses is cardiac stimulation.b
Principally a selective, direct stimulatory effect on 1-adrenergic receptors, but the mechanisms of
action are complex.100, 101, 110
In therapeutic doses, also mild 2- and 1-adrenergic receptor agonist effects.b
1-Adrenergic effects exert a potent positive inotropic effect, resulting in increased myocardial
contractility and cardiac output.110, b
Increased left ventricular filling pressure decreases in CHF.b, 110
Therapeutic doses cause decreased peripheral resistance; however, systolic blood pressure and
pulse pressure may remain unchanged or be increased because of augmented cardiac output.b
Usual doses do not substantially change heart rate.b
Coronary blood flow and myocardial oxygen consumption are usually increased because of
increased myocardial contractility.b
May facilitate AV conduction and shorten or cause no important change in intraventricular
conduction.b
Pulmonary vascular resistance may decrease if it is elevated initially and mean pulmonary artery
pressure may decrease or remain unchanged.b
Unlike dopamine, dobutamine does not seem to affect dopaminergic receptors and causes no renal
or mesenteric vasodilation; however, urine flow may increase because of increased cardiac output.
Advice to Patients
AHFS DI Essentials
Page 13 of 15
Importance of informing clinicians of existing or contemplated concomitant therapy, including

prescription and OTC drugs.a, b
Importance of women informing clinicians if they are or plan to become pregnant or plan to breastfeed.a
Importance of informing patients of other important precautionary information.a, b (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in
some individuals; consult specific product labeling for details.
Dobutamine Hydrochloride
Routes
Dosage Forms
For injection
Parenteral concentrate, for IV
infusion
Strengths
12.5 mg (of
dobutamine) per
mL*
Brand Names
Manufacturer
Dobutamine Hydrochloride Bedford,

for Injection (with sulfites) Hospira, Sicor
Dobutrex Solution (with Lilly

sodium bisulfite)
* available from one or more manufacturer, distributor, and/or repackager by generic
(nonproprietary) name
Dobutamine Hydrochloride in Dextrose
Dosage
Routes
Strengths
Forms
Brand Names
Manufacturer
0.5 mg (of dobutamine) Dobutamine in 5% Dextrose

Various
per mL (125 or 250 mg) Injection (with sulfites; Lifecare
Manufacturers
in 5% Dextrose*
[Braun, Hospira])
Dobutamine in 5% Dextrose
1 mg (of dobutamine)
Injection (with sulfites; Lifecare Various
per mL (250 or 500 mg)
Manufacturers
[Hospira, McGaw]; Viaflex
in 5% Dextrose*
[Baxter])
2 mg (of dobutamine) Dobutamine in 5% Dextrose
Various
per mL (500 mg) in 5% Injection (with sulfites; Lifecare
Manufacturers
Dextrose*
[Hospira]; Viaflex [Baxter])
Dobutamine in 5% Dextrose
4 mg (of dobutamine)
Injection (with sulfites; Lifecare Various
per mL (1000 mg) in
[Hospira, Braun, McGaw];
Manufacturers
5% Dextrose*
Viaflex [Baxter])
* available from one or more manufacturer, distributor, and/or repackager by generic
(nonproprietary) name
Injection,
Parenteral for IV
infusion
Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
Only references cited for selected revisions after 1984 are available electronically.
100. Leier CV, Unverferth DV. Dobutamine. Ann Intern Med. 1983; 99:490-6. [IDIS 176707]
[PubMed 6625384]
AHFS DI Essentials
Page 14 of 15
101. Ruffolo RR Jr. The mechanism of action of dobutamine. Ann Intern Med. 1984; 100:313-4.
[IDIS 181321] [PubMed 6140893]
102. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use; warning
statement: final rule [21 CFR Part 201]. Fed Regist. 1986; 51:43900-5.
103. Eli Lilly and Company. Dobutrex (dobutamine hydrochloride) solution prescribing
information. Indianapolis, IN: 1999 Feb.
104. Emergency Cardiac Care Committee and Subcommittees, American Heart Association.
Guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA. 1992;
268:2171-2302. [PubMed 1404767]
105. Robison-Strane SR, Bubik JS. Dobutamine-induced fever. Ann Pharmacother. 1992;
26:1523-4. [IDIS 306620] [PubMed 1482808]
106. Gensia Laboratories, Inc. Dobutamine hydrochloride injection prescribing information.
Irvine, CA; 1993 Apr.
107. Abbott Laboratories. Dobutamine in 5% dextrose injection prescribing information. North
Chicago, IL: 1998 Aug.
108. Food and Drug Administration. Dobutamine in 5% dextrose in flexible containers
[September 1, 1999; Abbott]. MedWatch drug labeling changes. Rockville, MD; September
1999. From FDA website ([Web]).
109. Food and Drug Administration. Dobutamine in 5% dextrose in plastic container [April 21,
1999; Baxter]. MedWatch drug labeling changes. Rockville, MD; April 1999. From FDA
website ([Web]).
110. The American Heart Association in Collaboration with the International Liaison Committee
on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care. Circulation. 2000; 102(Suppl I) I-132,I-328.
111. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of
patients with acute myocardial infarction: 1999 update: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on
Management of Acute Myocardial Infarction). Circulation. 1999; 100:1016-30. [IDIS 437967]
[PubMed 10468535]
112. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and
emergency cardiovascular care. Circulation. 2005; 112(Suppl I): IV1-211.
pdh. Schilling McCann JA, Publisher. Pharmacists drug handbook. 2nd ed. Philadelphia, PA:
Lippincott Williams and Wilkins and American Society of Health-System Pharmacists; 2003.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of
Health-System Pharmacists; 2007:545-55.
a. Baxter Healthcare Corporation. Dobutamine hydrochloride in 5% injection prescribing
information. Deerfield, IL; 2002 Jul.
b. AHFS drug information 2008. McEvoy GK, ed. Dobutamine. Bethesda, MD: American Society
of Health-System Pharmacists; 2008:1334-6
AHFS DI Essentials
Page 15 of 15
c. AHFS drug information 2008. McEvoy GK, ed. Dopamine. Bethesda, MD: American Society
of Health-System Pharmacists; 2008:1336-9

Dobu AHFS

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Dobu AHFS

Încărcat de

Drepturi de autor:

Formate disponibile

AHFS DI Essentials

Generic Name: Dobutamine Hydrochloride

To Make (final dilution

250 mcg (0.25 mg)/mL

Available as dobutamine hydrochloride; dosage expressed in terms of dobutamine.103, 107, a, b

Dextrose 5% in Ringer's injection, lactated

Importance of informing clinicians of existing or contemplated concomitant therapy, including

Dobutamine Hydrochloride Bedford,

Dobutrex Solution (with Lilly

0.5 mg (of dobutamine) Dobutamine in 5% Dextrose

S-ar putea să vă placă și